JNJ Jan 2025 85.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

75.05

0.00

(0.00%)

At close: 10:15AM EDT

Simply Wall St.
Johnson & Johnson's (NYSE:JNJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Johnson & Johnson's (NYSE:JNJ) stock increased significantly by 13% over the...
Zacks
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
PR Newswire
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of nipocalimab globally for the treatment of people living with generalized myasthenia gravis (gMG).